IntegraGen brought together its Oncology Scientific Committee at the 2016 American Society of Oncology (ASCO) Gastro Intestinal Symposium in San Francisco to discuss the results of its latest clinical study. This study evaluates the predictive effect of miR-31-3p expression on the efficacy of anti-EGFR therapy in patients with non-mutated metastatic colorectal cancer. The Scientific Committee brings together internationally renowned specialists in the management of patients with metastatic colorectal cancer.

IntegraGen's study shows that the level of expression of the microRNA biomarker hsa-miR-31-3p in the primary tumor of patients with non-mutated RAS metastatic colorectal cancer is predictive of the efficacy of anti-EGFR treatment in this population. To date, the company has accumulated clinical demonstrations of the biomarker's role in 8 separate, independent cohorts, involving a total of over 850 patients. These include three separate prospective randomized controlled trials (evidence level 1b). The clinical data accumulated on miR-31-3p over the last five years by IntegraGen have demonstrated and confirmed the robustness and consistency of results from one study to the next. The results obtained by IntegraGen in this field will enable it to contribute to efforts to personalize cancer treatment and optimize the individualization of treatments for patients with metastatic colorectal cancer.

"Based on a predefined expression threshold, we have shown on prospectively collected primary tumor samples in a randomized phase III trial, that patients whose tumors have miR-31-3p expression below this predefined threshold derive significant benefit from anti-EGFR therapy." said Bernard Courtieu, CEO of IntegraGen.. "We plan to present these results during the 2016 ASCO meeting in Chicago. In parallel, we are pursuing the development of a test based on the miR-31-3p biomarker in order to make it available to oncologists as part of the implementation of precision medicine strategies in the management of metastatic colorectal cancer. "